Wang, Ji Guang and Chia, Yook Chin and Chen, Chen Huan and Park, Sungha and Hoshide, Satoshi and Tomitani, Naoko and Kabutoya, Tomoyuki and Shin, Jinho and Turana, Yuda and Soenarta, Arieska Ann and Tay, Jam Chin and Buranakitjaroen, Peera and Nailes, Jennifer and Van Minh, Huynh and Siddique, Saulat and Sison, Jorge and Sogunuru, Guru Prasad and Sukonthasarn, Apichard and Teo, Boon Wee and Verma, Narsingh and Zhang, Yu Qing and Wang, Tzung Dau and Kario, Kazuomi (2020) What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia? The Journal of Clinical Hypertension, 22 (3). pp. 363-368. ISSN 1524-6175, DOI https://doi.org/10.1111/jch.13803.
Full text not available from this repository.Abstract
The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (≥80 years). Five classes of antihypertensive drugs, including β-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future. © 2020 Wiley Periodicals, Inc.
| Item Type: | Article |
|---|---|
| Funders: | National Natural Science Foundation of China (grants 81170245 and 91639203), State Ministry of Science and Technology (2018YFC1704902), Beijing, China, Shanghai Commissions of Science and Technology (15XD1503200), Health (grant 15GWZK0802 and a special grant for leading academics), Shanghai, China |
| Uncontrolled Keywords: | China; guideline; hypertension; management |
| Subjects: | R Medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 10 Jun 2020 01:03 |
| Last Modified: | 10 Jun 2020 01:03 |
| URI: | http://eprints.um.edu.my/id/eprint/24766 |
Actions (login required)
 |
View Item |
